Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis

Sabine Kayser, Mark J Levis, Richard F. Schlenk

Research output: Contribution to journalArticle

Abstract

Introduction: A number of tyrosine kinase inhibitors (TKIs) have been developed that inhibit the constitutively activated kinase activity caused by activating tyrosine kinase mutations, such as FLT3 or KIT, thus interrupting signaling pathways. Currently, midostaurin is the only approved TKI as monotherapy for aggressive systemic mastocytosis (SM), SM with associated hematological neoplasm, or mast cell leukemia displaying a KIT mutation as well as in combination with standard intensive chemotherapy for adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML). Areas covered: We provide a concise review of the pharmacology, tolerability and clinical efficacy of midostaurin and emerging new treatment options for ASM and FLT3-mutated AML. Expert commentary: Currently, midostaurin is the only approved TKI in aggressive SM, SM with associated hematological neoplasm, or mast cell leukemia inducing responses including complete remissions. With regard to AML, midostaurin is the first drug to receive regulatory approval in this indication in the molecularly defined subgroup of AML with FLT3 mutations. By introduction of this new standard in AML with FLT3 mutations, the bare has been raised for future approvals of next generation FLT3 inhibitors which will be based increasingly on head to head comparisons with midostaurin.

Original languageEnglish (US)
Pages (from-to)1-13
Number of pages13
JournalExpert Review of Clinical Pharmacology
DOIs
StateAccepted/In press - Oct 11 2017

Fingerprint

4'-N-benzoylstaurosporine
Systemic Mastocytosis
Acute Myeloid Leukemia
Protein-Tyrosine Kinases
Mast-Cell Leukemia
Mutation
Hematologic Neoplasms
Therapeutics
Phosphotransferases
Pharmacology
Drug Therapy

Keywords

  • Acute myeloid leukemia
  • advanced systemic mastocytosis
  • clinical trials
  • efficacy
  • FLT3 mutation
  • KIT mutation
  • midostaurin
  • pharmacology
  • tolerability
  • tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Cite this

Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis. / Kayser, Sabine; Levis, Mark J; Schlenk, Richard F.

In: Expert Review of Clinical Pharmacology, 11.10.2017, p. 1-13.

Research output: Contribution to journalArticle

@article{f7eb6d30a7514cf8bb43917dbb7fcef3,
title = "Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis",
abstract = "Introduction: A number of tyrosine kinase inhibitors (TKIs) have been developed that inhibit the constitutively activated kinase activity caused by activating tyrosine kinase mutations, such as FLT3 or KIT, thus interrupting signaling pathways. Currently, midostaurin is the only approved TKI as monotherapy for aggressive systemic mastocytosis (SM), SM with associated hematological neoplasm, or mast cell leukemia displaying a KIT mutation as well as in combination with standard intensive chemotherapy for adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML). Areas covered: We provide a concise review of the pharmacology, tolerability and clinical efficacy of midostaurin and emerging new treatment options for ASM and FLT3-mutated AML. Expert commentary: Currently, midostaurin is the only approved TKI in aggressive SM, SM with associated hematological neoplasm, or mast cell leukemia inducing responses including complete remissions. With regard to AML, midostaurin is the first drug to receive regulatory approval in this indication in the molecularly defined subgroup of AML with FLT3 mutations. By introduction of this new standard in AML with FLT3 mutations, the bare has been raised for future approvals of next generation FLT3 inhibitors which will be based increasingly on head to head comparisons with midostaurin.",
keywords = "Acute myeloid leukemia, advanced systemic mastocytosis, clinical trials, efficacy, FLT3 mutation, KIT mutation, midostaurin, pharmacology, tolerability, tyrosine kinase inhibitor",
author = "Sabine Kayser and Levis, {Mark J} and Schlenk, {Richard F.}",
year = "2017",
month = "10",
day = "11",
doi = "10.1080/17512433.2017.1387051",
language = "English (US)",
pages = "1--13",
journal = "Expert Review of Clinical Pharmacology",
issn = "1751-2433",
publisher = "Expert Reviews Ltd.",

}

TY - JOUR

T1 - Midostaurin treatment in FLT3-mutated acute myeloid leukemia and systemic mastocytosis

AU - Kayser, Sabine

AU - Levis, Mark J

AU - Schlenk, Richard F.

PY - 2017/10/11

Y1 - 2017/10/11

N2 - Introduction: A number of tyrosine kinase inhibitors (TKIs) have been developed that inhibit the constitutively activated kinase activity caused by activating tyrosine kinase mutations, such as FLT3 or KIT, thus interrupting signaling pathways. Currently, midostaurin is the only approved TKI as monotherapy for aggressive systemic mastocytosis (SM), SM with associated hematological neoplasm, or mast cell leukemia displaying a KIT mutation as well as in combination with standard intensive chemotherapy for adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML). Areas covered: We provide a concise review of the pharmacology, tolerability and clinical efficacy of midostaurin and emerging new treatment options for ASM and FLT3-mutated AML. Expert commentary: Currently, midostaurin is the only approved TKI in aggressive SM, SM with associated hematological neoplasm, or mast cell leukemia inducing responses including complete remissions. With regard to AML, midostaurin is the first drug to receive regulatory approval in this indication in the molecularly defined subgroup of AML with FLT3 mutations. By introduction of this new standard in AML with FLT3 mutations, the bare has been raised for future approvals of next generation FLT3 inhibitors which will be based increasingly on head to head comparisons with midostaurin.

AB - Introduction: A number of tyrosine kinase inhibitors (TKIs) have been developed that inhibit the constitutively activated kinase activity caused by activating tyrosine kinase mutations, such as FLT3 or KIT, thus interrupting signaling pathways. Currently, midostaurin is the only approved TKI as monotherapy for aggressive systemic mastocytosis (SM), SM with associated hematological neoplasm, or mast cell leukemia displaying a KIT mutation as well as in combination with standard intensive chemotherapy for adult patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML). Areas covered: We provide a concise review of the pharmacology, tolerability and clinical efficacy of midostaurin and emerging new treatment options for ASM and FLT3-mutated AML. Expert commentary: Currently, midostaurin is the only approved TKI in aggressive SM, SM with associated hematological neoplasm, or mast cell leukemia inducing responses including complete remissions. With regard to AML, midostaurin is the first drug to receive regulatory approval in this indication in the molecularly defined subgroup of AML with FLT3 mutations. By introduction of this new standard in AML with FLT3 mutations, the bare has been raised for future approvals of next generation FLT3 inhibitors which will be based increasingly on head to head comparisons with midostaurin.

KW - Acute myeloid leukemia

KW - advanced systemic mastocytosis

KW - clinical trials

KW - efficacy

KW - FLT3 mutation

KW - KIT mutation

KW - midostaurin

KW - pharmacology

KW - tolerability

KW - tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85031099709&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031099709&partnerID=8YFLogxK

U2 - 10.1080/17512433.2017.1387051

DO - 10.1080/17512433.2017.1387051

M3 - Article

C2 - 28960095

AN - SCOPUS:85031099709

SP - 1

EP - 13

JO - Expert Review of Clinical Pharmacology

JF - Expert Review of Clinical Pharmacology

SN - 1751-2433

ER -